Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

indium In 111-FL-020

A radioconjugate composed of FL-020, a human prostate-specific membrane antigen (PSMA)-targeting ligand, conjugated to the radioisotope indium In 111, with potential imaging activity during single photon emission computed tomography (SPECT)/computed tomography (PET/CT). Upon administration of indium In 111-FL-020, FL-020 targets and binds to PSMA-expressing tumor cells, followed by internalization and retention of the radioisotope. This allows for imaging of PSMA-expressing tumor cells using gamma scintigraphy. PSMA, a tumor-associated antigen (TAA) and type II transmembrane protein, is expressed on the membrane of prostatic epithelial cells and overexpressed on prostate tumor cells as well as a variety of other solid tumors.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:[111In]-FL-020
[111In]In-FL-020
indium In 111 FL-020
indium In 111-labeled FL-020
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search